1. Generics Bulletin
  2. >>Archive

Alvogen is first with Revlimid rival in EU

Alvogen is claiming the first approvals in “several European countries” for its generic version of Celgene’s Revlimid (lenalidomide) capsules, after its Lotus Pharmaceuticals affiliate “successfully concluded multiple registration procedures” for the oncology drug. Lotus’ lenalidomide has been approved in European markets in seven strengths: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg capsules.

Alvogen is claiming the first approvals in “several European countries” for its generic version of Celgene’s Revlimid (lenalidomide) capsules, after its Lotus Pharmaceuticals affiliate “successfully concluded multiple registration procedures” for the oncology drug. Lotus’ lenalidomide has been approved in European markets in seven strengths: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg and 25mg capsules.

Noting that Iceland acted as the reference member state (RMS) in the decentralised marketing-authorisation procedure, Lotus said its European application for lenalidomide had been approved around a year after the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.

Is Towa’s Guidance For 2024 ‘Somewhat Mediocre?’

 
• By Dean Rudge

Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.

Publisher’s Spotlight: Citeline News And Insights App

 
• By Generics Bulletin Team

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from Generics Bulletin

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By Dean Rudge

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.

Abiogen And mAbxience Join Forces In Italy

 
• By Dave Wallace

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.